Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma
- Sponsor
- University of Luebeck
- Study ID
- NCT01370135
- Status
- Completed
Conditions
- Neovascular Glaucoma
- Rubeosis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- 0.5mg intraocular Ranibizumab (Lucentis) — DRUGshort- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections as adjuvant for patients with rubeosis and neovascular glaucoma
Study Details
Proliferative ischemic retinopathies lead to a formation of abnormal vessels on the iris surface induced by an increased level of vascular endothelial growth factor (VEGF). In progressive stages fibrovascular membranes occlude the anterior chamber angle which inhibits aqueous outflow resulting in neovascular glaucoma. The increased intraocular pressure is often difficult to control and frequently results in loss of vision. The aim of this study is to analyze the short- and long-term outcome after adjuvant intraocular Ranibizumab application in patients with neovascular glaucoma and rubeosis and to analyze the role of ranibizumab within a holistic treatment regime.
Key Dates
- First listed
- Jun 9, 2011
- Start date
- Nov 30, 2008
- Status verified
- Jan 2013
- Primary completion
- Apr 30, 2011
- Completion
- Jul 31, 2011
Study Design
- Enrollment
- 20 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Lucentis (Ranibizumab)
Primary Outcome Measure
change of degree of iris rubeosis [ Time Frame: 12 Months ]